Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More

CD267 Rat anti-Human, PE, Clone: 1A1-K21-M22, BD

Rat Monoclonal Antibody

Supplier:  BD Biosciences 558414

Catalog No. BDB558414


Only null left
Add to Cart

Description

Description

The 1A1-K21-M22 monoclonal antibody specifically binds to CD267 which is also known as TACI (Transmembrane Activator and CAML Interactor). CD267 is a member of the of the Tumor Necrosis Factor Receptor (TNFR) Superfamily and is encoded by the TNFRSF13B gene. This 32 kDa type III transmembrane protein receptor binds to the ligands, BAFF (TNFSF13B/BLyS/CD257) and APRIL (TNFSF13/CD256). Ligand-bound CD267 transduces signals leading to the activation of transcription factors including NFAT, AP1, and NF-kappa-B. CD267 is expressed most notably on maturing subsets of B cells and myeloma cells. In CD267 deficient mice, B cell numbers are increased and mice develop autoimmune disorders suggesting that CD267 plays an important role in the regulation of B cell homeostasis.

TRUSTED_SUSTAINABILITY
Specifications

Specifications

CD267
Monoclonal
0.2mg/mL
TACI; TNFRSF13B; Tumor necrosis factor receptor 13B; TNFRSF14B2; CVID2
Rat
0.1 mg
Immunology
Human
IgG2a κ
Flow Cytometry
1A1-K21-M22
PE
Aqueous buffered solution containing ≤0.09% sodium azide.
Human RBL
RUO
Primary
Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze.
Product Suggestions

Product Suggestions

Videos
SDS
Documents

Documents

Product Certifications
Promotions

Promotions

Product Content Correction

Your input is important to us. Please complete this form to provide feedback related to the content on this product.

Product Title

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.

Your feedback has been submitted: Thank you for helping us improve our website.